Ionis Pharmaceuticals (IONS) announces Roche has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
Go back to Ionis Pharmaceuticals (IONS) announces Roche has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease
March 22, 2021 4:01 PM EDT
Ionis Pharmaceuticals (NASDAQ: IONS) Halted, News Pending
...
More
